Delcath Systems, Inc. $DCTH Shares Sold by Apis Capital Advisors LLC

Apis Capital Advisors LLC decreased its holdings in Delcath Systems, Inc. (NASDAQ:DCTH) by 44.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 136,000 shares of the company’s stock after selling 110,000 shares during the quarter. Apis Capital Advisors LLC owned about 0.39% of Delcath Systems worth $1,374,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. California State Teachers Retirement System purchased a new position in Delcath Systems in the 2nd quarter worth $26,000. Russell Investments Group Ltd. purchased a new position in Delcath Systems in the 3rd quarter worth $29,000. Tower Research Capital LLC TRC purchased a new position in Delcath Systems in the 2nd quarter worth $40,000. Legal & General Group Plc purchased a new position in Delcath Systems in the 2nd quarter worth $46,000. Finally, The Manufacturers Life Insurance Company purchased a new position in Delcath Systems in the 2nd quarter worth $151,000. Institutional investors and hedge funds own 61.12% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on DCTH. Zacks Research lowered Delcath Systems from a “hold” rating to a “strong sell” rating in a research note on Monday, May 11th. BTIG Research reduced their price objective on Delcath Systems from $23.00 to $19.00 and set a “buy” rating for the company in a research note on Thursday, February 26th. Evercore set a $27.00 price objective on Delcath Systems in a research note on Thursday, February 26th. Wall Street Zen lowered Delcath Systems from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Finally, Weiss Ratings upgraded Delcath Systems from a “sell (d)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Five investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $22.50.

Delcath Systems Price Performance

Shares of Delcath Systems stock opened at $11.93 on Thursday. The stock has a market cap of $411.82 million, a P/E ratio of 1,193.00 and a beta of 0.54. The stock’s 50 day simple moving average is $10.95 and its 200-day simple moving average is $10.18. Delcath Systems, Inc. has a 1-year low of $8.12 and a 1-year high of $14.62.

Delcath Systems (NASDAQ:DCTH) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.07. The firm had revenue of $24.99 million for the quarter, compared to analyst estimates of $23.51 million. Delcath Systems had a net margin of 0.62% and a return on equity of 0.51%. As a group, research analysts expect that Delcath Systems, Inc. will post -0.88 EPS for the current fiscal year.

About Delcath Systems

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.